BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The company's shares are expected to trade on a split adjusted basis beginning February 10, 2025.
For comments and feedback: editorial@rttnews.com